Co-mutations are associated with prognosis and drug sensitivity [233, 234], especially the response to checkpoint inhibition [235]; a study involving 330 advanced KRAS mutant lung cancer patients showed that patients with KRAS/KEAP1/NFE2L2 co-mutation had shorter OS and worse response to both platinum-based chemotherapy and immune therapy [236]. This evidence concerns the gene KEAP1 and lung carcinoma.